inclusion criteria: * adults ≥18 years of age * positive ncov2 pcr test by nasopharyngeal, oral, saliva, or respiratory sample * clinical signs, symptoms, and respiratory status consistent with severe covid-19 * score of 5-7 on the who ordinal scale * onset of severe covid-19 symptoms ≤7 days of study enrollment * subject is in-patient at time of randomization to study treatment * subject or legally authorized representative is willing and able to provide informed consent, and agrees for subject to comply with planned study procedures including reproductive requirements

inclusion criteria: * adults ≥18 years of age * positive ncov2 pcr test by nasopharyngeal, oral, saliva, or respiratory sample * clinical signs, symptoms, and respiratory status consistent with severe covid-19 * score of 5-7 on the who ordinal scale * onset of severe covid-19 symptoms ≤7 days of study enrollment * subject is in-patient at time of randomization to study treatment * subject or legally authorized representative is willing and able to provide informed consent, and agrees for subject to comply with planned study procedures including reproductive requirements

inclusion criteria: adults ≥18 years of age positive ncov2 pcr test by nasopharyngeal, oral, saliva, or respiratory sample clinical signs, symptoms, and respiratory status consistent with severe covid-19 score of 5-7 on the who ordinal scale onset of severe covid-19 symptoms ≤7 days of study enrollment subject is in-patient at time of randomization to study treatment subject or legally authorized representative is willing and able to provide informed consent, and agrees for subject to comply with planned study procedures including reproductive requirements

inclusion criteria: adults ≥18 years of age positive ncov2 pcr test by nasopharyngeal, oral, saliva, or respiratory sample clinical signs, symptoms, and respiratory status consistent with severe covid-19 score of 5-7 on the who ordinal scale onset of severe covid-19 symptoms ≤7 days of study enrollment subject is in-patient at time of randomization to study treatment subject or legally authorized representative is willing and able to provide informed consent, and agrees for subject to comply with planned study procedures including reproductive requirements

inclusion criteria: - adults ≥18 years of age - positive ncov2 pcr test by nasopharyngeal, oral, saliva, or respiratory sample - clinical signs, symptoms, and respiratory status consistent with severe covid-19 - severe disease: requiring mechanical ventilation or oxygen, a spo2 ≤ 94% on room air, or tachypnoea (respiratory rate ≥ 24 breaths/min) - symptom onset ≤7 days of study enrollment - subject is in-patient at time of randomization to study treatment - subject or legally authorized representative is willing and able to provide informed consent

inclusion criteria: - adults ≥18 years of age - positive ncov2 pcr test by nasopharyngeal, oral, saliva, or respiratory sample - clinical signs, symptoms, and respiratory status consistent with severe covid-19 - severe disease: requiring mechanical ventilation or oxygen, a spo2 ≤ 94% on room air, or tachypnoea (respiratory rate ≥ 24 breaths/min) - symptom onset ≤7 days of study enrollment - subject is in-patient at time of randomization to study treatment - subject or legally authorized representative is willing and able to provide informed consent